PCOS (Polycystic Ovary Syndrome) Racial and Ethnic Disparities

How Common Is PCOS Across Racial and Ethnic Groups?

PCOS is one of the most common endocrine conditions in reproductive-age women, but prevalence estimates shift depending on the diagnostic criteria used and the population studied. The Rotterdam criteria, which require two of three features (oligo-ovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology), tend to capture broader prevalence than the older NIH 1990 criteria.

A 2010 community-based study by March et al. (N=728, unselected Australian women) estimated prevalence at 17.8% using Rotterdam criteria and 8.7% using NIH criteria [1]. When U.S. Data are stratified by race, striking differences emerge.

Prevalence in Black Women

A prospective cohort analysis using the Coronary Artery Risk Development in Young Adults (CARDIA) study found that Black women had a PCOS prevalence of approximately 8.0% vs. 4.8% in white women when NIH criteria were applied [2]. Black women in that cohort also had higher fasting insulin and a greater prevalence of acanthosis nigricans, signaling more pronounced insulin resistance.

Prevalence in Hispanic Women

Hispanic women show PCOS prevalence rates between 13 and 19% in clinic-based samples, with metabolic syndrome co-occurring in up to one-third of affected individuals [3]. The elevated prevalence tracks closely with higher rates of type 2 diabetes and obesity in this population, though causality is bidirectional.

Prevalence in Asian Women

East and South Asian women present a distinct epidemiological picture. A large cross-sectional study in China (N=15,924) reported a PCOS prevalence of 5.6% using Rotterdam criteria, but metabolic comorbidities appeared at significantly lower BMIs than in Western cohorts [4]. South Asian women in the United Kingdom showed similarly elevated androgen levels and insulin resistance at BMIs considered "normal" by standard Western cutoffs.

Diagnostic Delays and Barriers by Race and Ethnicity

Diagnosis takes longer for women from racial and ethnic minority groups. This is not a minor administrative inconvenience. Delayed diagnosis translates to delayed treatment of anovulatory infertility, unmanaged hyperandrogenism, and years of untreated insulin resistance that accelerate cardiovascular risk.

The Hirsutism Scoring Problem

The modified Ferriman-Gallwey (mFG) score is the standard clinical tool for quantifying hirsutism, but it was developed and validated predominantly in white women. Black and Asian women often have different baseline hair-growth patterns, making the same mFG threshold less sensitive or less specific depending on the group.

A 2017 analysis published in the Journal of Clinical Endocrinology and Metabolism found that mFG scores underestimated clinically meaningful androgen excess in Black women when a single universal threshold was applied [5]. The 2023 International Evidence-Based PCOS Guideline (developed by Monash University in partnership with the European Society of Human Reproduction and Embryology) explicitly states: "Ethnic variation in hair growth patterns means that a lower Ferriman-Gallwey threshold may be appropriate in some populations" [6].

Insurance and Access Disparities

Structural barriers compound clinical ones. Hispanic women of reproductive age have uninsured rates nearly twice those of non-Hispanic white women, limiting access to the gynecologic or endocrinologic evaluation needed for diagnosis [7]. Black women report higher rates of symptom dismissal in primary care settings, a pattern documented across multiple chronic conditions and not unique to PCOS but particularly consequential given the metabolic stakes.

Biochemical vs. Clinical Hyperandrogenism

Because hirsutism scoring may miss hyperandrogenism in certain groups, measuring serum free testosterone and calculating free androgen index becomes especially important in Black and Asian women. The 2023 PCOS Guideline recommends calculated free testosterone or free androgen index as the preferred biochemical measures, with total testosterone as an acceptable alternative [6].

Metabolic Risk Differences Across Racial Groups

The metabolic consequences of PCOS do not distribute equally. Insulin resistance is present in 65 to 80 percent of women with PCOS regardless of weight [8], but its downstream effects are shaped substantially by race, ethnicity, and socioeconomic environment.

Insulin Resistance and Type 2 Diabetes Risk

A meta-analysis by Moran et al. (2010, 35 studies) found that women with PCOS had a 4-fold increased odds of developing impaired glucose tolerance and type 2 diabetes compared to age-matched controls [9]. When stratified by ethnicity, South Asian and Hispanic women with PCOS showed the steepest progression curves from normal glucose to impaired fasting glucose.

The American Diabetes Association recommends screening for prediabetes in women with PCOS using a fasting glucose, 2-hour oral glucose tolerance test (OGTT), or HbA1c [10]. An OGTT is preferred over HbA1c alone in this population because HbA1c may underestimate dysglycemia in women with high erythrocyte turnover.

Cardiovascular Risk Factors

Black women with PCOS carry a disproportionate cardiovascular burden. Data from the CARDIA study showed that Black women with PCOS had higher resting blood pressure, higher triglycerides, and lower HDL cholesterol than white women with PCOS at matched BMI levels [2]. These differences persisted after adjusting for socioeconomic status, suggesting a biological component in addition to structural drivers.

The Endocrine Society's 2018 PCOS Clinical Practice Guideline recommends cardiovascular risk screening (lipid panel, blood pressure, glucose) at diagnosis and every 1 to 2 years thereafter for women with additional risk factors [11].

The BMI Paradox in Asian Women

Standard BMI cutoffs (<25 normal, 25 to 29.9 overweight, >30 obese) do not adequately capture cardiometabolic risk in East and South Asian women. The World Health Organization has acknowledged that metabolic risk in Asian populations may begin at a BMI of 23, roughly 2 BMI units lower than the conventional threshold [12].

This has direct implications for PCOS management. A clinician evaluating an East Asian woman with PCOS and a BMI of 24 might incorrectly categorize her as low metabolic risk using standard criteria. The 2023 International PCOS Guideline recommends using ethnicity-specific waist-circumference cut-offs: 80 cm for South Asian, Chinese, Japanese, and South and Central American women, compared to 88 cm for white women [6].

Reproductive Outcomes and Fertility Disparities

PCOS is the most common cause of anovulatory infertility. Fertility treatment access and outcomes differ meaningfully by race.

Ovulation Induction Response

Letrozole (2.5 to 7.5 mg, days 3 to 7 of the cycle) is the first-line ovulation induction agent per the 2023 PCOS Guideline, having displaced clomiphene citrate after the PPCOS II trial (N=750) demonstrated superior live-birth rates with letrozole [6, 13]. However, most major ovulation induction trials have enrolled predominantly white women, leaving clinicians with limited race-stratified data on optimal dosing or response rates.

ART Access and Outcomes

Black women undergoing assisted reproductive technology (ART) have lower live-birth rates per retrieval cycle than white women, even after controlling for age and diagnosis. A 2020 JAMA analysis (N=175,000 ART cycles from the CDC's National ART Surveillance System) found that Black patients had a live-birth rate of 28.4% vs. 38.4% for white patients across all diagnoses [14]. Whether PCOS-specific subgroup outcomes mirror this gap is not yet well-characterized, but the overall disparity signal is consistent enough to warrant clinical attention and patient counseling.

Psychological and Quality-of-Life Disparities

PCOS carries a substantial psychological burden. Depression affects approximately 34% of women with PCOS, and anxiety affects roughly 45%, according to a 2018 systematic review and meta-analysis (N=7,238 women) [15]. These rates exceed those of age-matched women without PCOS by 3- to 4-fold.

Race-Specific Psychological Burden

Body image concerns tied to hirsutism, acne, and weight gain are reported across all racial groups, but the cultural context shapes their impact differently. A qualitative study published in Human Reproduction (2020) found that Black women with PCOS described experiencing a "double stigma," managing both the condition's symptoms and racialized medical encounters in which their concerns were minimized [16].

Hispanic women in the same literature reported cultural pressures around fertility that intensified emotional distress when PCOS caused anovulatory infertility. Screening tools like the PHQ-9 and GAD-7, while not PCOS-specific, should be administered at diagnosis and during follow-up visits.

Culturally Adapted Screening

Standard quality-of-life instruments for PCOS, including the PCOSQ (Polycystic Ovary Syndrome Questionnaire), were validated largely in white, English-speaking populations. Translations and cultural adaptations exist for Spanish and Mandarin but remain limited for other languages. Clinicians managing diverse patient panels may consider supplementing with validated general instruments like the SF-36 until PCOS-specific tools are more broadly validated.

Treatment Response Variations by Race and Ethnicity

First-line treatments for PCOS include lifestyle modification, metformin, combined oral contraceptives, and letrozole for ovulation induction. Evidence on differential treatment response by race is limited but accumulating.

Metformin

Metformin 500 to 2,000 mg daily improves insulin sensitivity, lowers androgen levels, and restores ovulatory cycles in a meaningful proportion of women with PCOS [17]. South Asian women in observational cohorts appear to respond at least as well as white women, consistent with the higher baseline insulin resistance in that group. The 2023 PCOS Guideline recommends metformin as an adjunct to lifestyle therapy for metabolic management in women with a BMI >25 (or ethnicity-adjusted equivalent) [6].

Combined Oral Contraceptives

Combined oral contraceptives (COCs) remain the standard for managing hyperandrogenism and menstrual irregularity in women not pursuing pregnancy. No large randomized trial has stratified COC response for PCOS by race. Clinicians should recognize that venous thromboembolism (VTE) risk with COCs is baseline-elevated in women with PCOS and may differ across racial groups given different baseline clotting factor profiles.

GLP-1 Receptor Agonists

GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), are not FDA-approved specifically for PCOS but are increasingly prescribed off-label for weight management and insulin sensitization in this population. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg subcutaneously weekly produced 14.9% mean body-weight reduction at 68 weeks vs. 2.4% with placebo (P<0.001) [18]. Race-stratified subgroup data from STEP-1 showed consistent directional benefit across Black, Hispanic, and white participants, though absolute weight-loss magnitude varied.

Emerging data from smaller PCOS-specific trials suggest GLP-1 agonists may restore ovulatory cycles and reduce androgen levels independent of weight loss. Prescribers should document the off-label rationale and counsel patients on the absence of PCOS-specific FDA approval.

Inositol Supplementation

Myo-inositol (2,000 mg twice daily) and D-chiro-inositol have been studied as insulin sensitizers in PCOS. A 2019 Cochrane-adjacent systematic review found moderate-quality evidence that myo-inositol improves ovulation rates compared to placebo [19]. No adequately powered race-stratified data exist for inositol.

What Guidelines Say About Equitable PCOS Care

The 2023 International Evidence-Based PCOS Guideline, the most comprehensive current reference, was developed with input from 71 organizations across 71 countries and represents the clearest available statement on equitable care. It explicitly states the need to "consider ethnicity in the assessment of clinical features of hyperandrogenism and metabolic risk" and recommends that "ethnicity-specific anthropometric cut-offs be applied when assessing adiposity and cardiometabolic risk" [6].

The Endocrine Society 2018 Guideline adds that oral glucose tolerance testing is preferred for dysglycemia screening in high-risk groups, and notes that Southeast Asian, Hispanic, and Black women with PCOS are at elevated risk and should be screened at diagnosis regardless of BMI [11].

Neither guideline provides specific recommendations on how to address structural access barriers, reflecting a gap in the formal evidence base that clinical teams must address through practice-level interventions.

Clinical Recommendations for Practitioners

Equitable PCOS care requires protocol adjustments, not just awareness. Specific steps include the following.

Use ethnicity-adjusted waist-circumference cutoffs: 80 cm for South Asian, East Asian, and Latin American women; 88 cm for white women; current data are insufficient to specify a separate cut-off for Black women, and clinical judgment should apply [6].

Order biochemical androgen testing routinely in Black and Asian women given the lower sensitivity of mFG scoring in these groups. Free testosterone or calculated free androgen index is preferred over total testosterone [6].

Screen for dysglycemia with an OGTT at diagnosis in Hispanic, South Asian, and Black women with PCOS, regardless of BMI or apparent weight status [11].

Use the PHQ-9 at diagnosis and at annual visits. Depression and anxiety are underdiagnosed in minority women with chronic conditions, and PCOS amplifies that baseline risk [15].

Counsel patients on letrozole as first-line ovulation induction therapy (2.5 mg initially, titrating to 7.5 mg based on response), and document that clomiphene is now a second-line agent per guideline update [6, 13].

For women with BMI above ethnicity-adjusted thresholds and insufficient response to lifestyle modification alone, consider metformin 500 to 1,000 mg twice daily or, in appropriate candidates, a GLP-1 receptor agonist with documented off-label rationale [6, 17].